Home › Lung Cancer › Pennsylvania › Lancaster
Lung Cancer clinical trials in Lancaster, PA
3 studies for Lung Cancer are looking for participants at sites in and around Lancaster (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RecruitingPhase 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068), Lancaster
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
RecruitingPhase 3
- Lancaster General Ann B Barshinger Cancer Institute, Lancaster
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
RecruitingObservational study
- US Digestive Health at Lancaster, Lancaster
About Lung Cancer
Lung cancer forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women.
More about Lung Cancer on MedlinePlus
Lung Cancer trials in other cities
- Houston, TX78 studies
- Boston, MA62 studies
- New York City, NY60 studies
- Los Angeles, CA45 studies
- Arlington, VA41 studies
- Washington, DC41 studies
- Chicago, IL41 studies
- Nashville, TN40 studies
- Baltimore, MD40 studies
- St. Louis, MO39 studies
- Columbus, OH37 studies
- Philadelphia, PA36 studies
Other studies in Lancaster
- Non-Small Cell Lung Cancer7 studies
- Heart Failure5 studies
- Cardiovascular Disease5 studies
- Prostate Cancer4 studies
- Metastatic Cancer4 studies
- Breast Cancer4 studies
- Bladder Cancer3 studies
- Amblyopia3 studies
- Heart Diseases3 studies
- Non-Muscle Invasive Bladder Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.